Fiagon
Key Facts
| Invested since | 2009 |
| Based in | Brandenburg |
About the company
Fiagon develops a new medical navigation system for intraoperative process control and positioning of instruments for ENT, head-/ neck- and neurosurgery.
Do you want to
know more about this company?
Fiagon in the news
Zum Artikel
The HTGF-portfolio company FIAGON AG SECURES A PATENT LICENSE AGREEMENT WITH GE HEALTHCARE, AND FIAGON AG HAS RECEIVED NOTICE OF 510(k) CLEARANCE FROM THE FDA as well as chinese CFDA approval
More startups from Life Sciences
Treatment of sustainable plaque in coronary arteries through our proprietary catheter based device.
To the complete profileof Cryotherapeutics
TRIM TX is developing best-in-class Gamma-Secretase-Stabilizers (GSS) for the prevention and treatment of Alzheimer Disease.
To the complete profileof TRIM TX
Exit
Provecs Medical develops novel products from its platform technology for cancer treatment by specific activation of the immune system. Exit since July 2015.
To the complete profileof Provecs Medical
Refoxy is the first biotech company purposely developing FOXO3 activators to leverage the therapeutic effects related to this master regulator of biological homeostasis. Refoxy’s discovery platform, F.act finder (FOXO activator …
To the complete profileof Refoxy Pharma
Hamburg-based COLIPI is developing an industrial biotechnological process that transforms climate-damaging CO2 and carbon-containing industrial waste into Climate Oil. This product serves as a sustainable and climate-neutral alternative to palm …
To the complete profileof COLIPI
Verovaccines is a biopharmaceutical company developing combination vaccines for animal health using a new proprietary technology. These vaccines offer several solutions for medical and industry needs in animal health: new …
To the complete profileof VEROVACCiNES
Nebula Biocides GmbH was founded in 2019 as a spin-off from the Leibniz Institute for Plasma Science and Technology (INP) by the scientists Dr. Jörn Winter, Dr. Ansgar Schmidt-Bleker and …
To the complete profileof Nebula Biocides
Exit
Corimmun is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative peptide and biological drugs in indications with unmet medical needs. Exit since …
To the complete profileof Corimmun
Inovedis is developing a new surgical technique for rotator cuff ruptures based on a PEEK implant. This injury is by so far the most typical shoulder injury. The patented SINEFIX …
To the complete profileof Inovedis
Exit
KINAXO supports pharmaceutical companies in the development of targeted drugs and predictive biomarkers for personalized healthcare. Exit since Feb. 2011. Purchaser: Evotec AG
To the complete profileof KINAXO
The Trans-Duodenal Barrier developed by TDC is a patented endoscopic transduodenal bypass implant for combined diabetes/obesity therapy that atraumatically prevents nutrient absorption in the duodenum and delays gastric emptying. The …
To the complete profileof trans.duodenal.concepts
Coramaze Technologies develops an innovative, highly differentiated, transcatheter tricuspid valve repair system, called TriPair. Headquartered in Germany with an R&D hub in Israel, we promote health equity by offering a …
To the complete profileof coramaze